tirzepatide optic neuropathy Is (a GIP/GLP‑1 dual agonist) safe to initiate in a patient with a history of anterior ischemic (AION) or other risk factors for optic nerve ischemia? Ophthalmic complications observed in patients
Description
Individuals with minimal weight to lose (BMI under 27 kg/m without comorbidities) do not meet clinical criteria for pharmacological weight loss treatment
Generally, tirzepatide may be prescribed to obese patients (defined as having a BMI of 30 or higher) or overweight patients (with a BMI of 27 or higher) who also have a weight-related health condition, such as high cholesterol or sleep apnea
Protein-Enriched Liquid Preloads Varying in Macronutrient Content: appetite, energy intake, and biomarkers of satiety
Strategic approaches to protein consumption can help patients maintain adequate nutrition while minimizing gastrointestinal discomfort during treatment
You just do not feel driven to eat as often or as much
Our fee includes a consultation with a licensed provider, a customized treatment plan, and ongoing support to help you achieve your goals
